View in EDS

Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study

Saved in:
Bibliographic Details
Title: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study
Authors: Zeng, X, Shi, S, Sun, L, Hua, B, Gilkeson, GS, Wang, H, Lu, L, Zhang, H, Liang, J, Hou, Y
Source: Annals of the Rheumatic Diseases. 69:1423-1429
Publisher Information: Elsevier BV, 2010.
Publication Year: 2010
Subject Terms: Adult, Male, 0301 basic medicine, Adolescent, Lupus Erythematosus, Systemic - immunology - therapy, Mesenchymal Stem Cell Transplantation, T-Lymphocytes, Regulatory, Antibodies, Young Adult, 03 medical and health sciences, Humans, Lupus Erythematosus, Systemic, Transplantation, Homologous, Antibodies, Antinuclear - blood, Antinuclear - blood, Child, 0303 health sciences, Lupus Erythematosus, Systemic - immunology - therapy, Mesenchymal Stem Cell Transplantation - adverse effects - methods, DNA, Lupus Nephritis, 3. Good health, Treatment Outcome, Antibodies, Antinuclear, Female, Epidemiologic Methods, Glomerular Filtration Rate
Description: To determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in refractory systemic lupus erythematosus (SLE).A total of 15 patients with persistently active SLE underwent MSCT. Outcome was evaluated by changes in the SLE disease activity index (SLEDAI), serological features (anti-nuclear antibodies and anti-double-stranded DNA (anti-dsDNA)), renal function and percentage of peripheral blood regulatory T cells.From 11 March 2007 to 4 November 2008, 15 patients with persistently active SLE were enrolled and underwent MSCT. The mean follow-up period was 17.2+/-9.5 months. A total of 13 patients have been followed for more than 12 months. All patients clinically improved following treatment with mesenchymal stem cells with a marked decrease in the SLEDAI score and 24 h proteinuria. At 12-month follow-up, SLEDAI scores decreased from 12.2+/-3.3 to 3.2+/-2.8 and proteinuria decreased from 2505.0+/-1323.9 to 858.0+/-800.7 mg/24 h (all p
Document Type: Article
Language: English
ISSN: 0003-4967
DOI: 10.1136/ard.2009.123463
Access URL: https://ard.bmj.com/content/69/8/1423.full.pdf
https://pubmed.ncbi.nlm.nih.gov/20650877
http://ard.bmj.com/content/69/8/1423.long
http://hub.hku.hk/bitstream/10722/129504/1/Content.pdf
https://hub.hku.hk/handle/10722/129504
https://www.ncbi.nlm.nih.gov/pubmed/20650877
https://europepmc.org/article/MED/20650877
http://ard.bmj.com/content/69/8/1423.full
http://hdl.handle.net/10722/129504
Rights: Elsevier TDM
CC BY NC ND
Accession Number: edsair.doi.dedup.....d3ab69d07837a18314abed8c2dbcf09a
Database: OpenAIRE
Description
Abstract:To determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in refractory systemic lupus erythematosus (SLE).A total of 15 patients with persistently active SLE underwent MSCT. Outcome was evaluated by changes in the SLE disease activity index (SLEDAI), serological features (anti-nuclear antibodies and anti-double-stranded DNA (anti-dsDNA)), renal function and percentage of peripheral blood regulatory T cells.From 11 March 2007 to 4 November 2008, 15 patients with persistently active SLE were enrolled and underwent MSCT. The mean follow-up period was 17.2+/-9.5 months. A total of 13 patients have been followed for more than 12 months. All patients clinically improved following treatment with mesenchymal stem cells with a marked decrease in the SLEDAI score and 24 h proteinuria. At 12-month follow-up, SLEDAI scores decreased from 12.2+/-3.3 to 3.2+/-2.8 and proteinuria decreased from 2505.0+/-1323.9 to 858.0+/-800.7 mg/24 h (all p
ISSN:00034967
DOI:10.1136/ard.2009.123463